One question that TSB must ask is why do we get the same old analysis from the analysts? Could it be that they lack the clinical knowledge to put their reputations on the line with potential emerging technologies? When will we ever get a coherent analysis on some of the facet technologies that are starting to make headway in the industry? And I am not talking about Facet Solutions either! Whether you agree with it or not there is a market. When will we get a real analysis regarding some of the bio-materials that are utilized in fusion? Is the industry that tainted that we rely on opinions from analysts that have a vested interest in the success or failure of a product?
TSB can guarantee that next year's meeting will be no different. It's time that things change or companies start to boycott NASS. What do our readers think?